Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma

International Journal of Biological Markers

Volumn 25, Issue 3, 2010, Pages 164-170

  Cristaudo, Alfonso ^a   Foddis, Rudy ^a   Bonotti, Alessandra ^a   Simonini, Silvia ^a   Vivaldi, Agnese ^a   Guglielmi, Giovanni ^a   Ambrosino, Nicolino ^b   Canessa, Pier Aldo ^c   Chella, Antonio ^b   Lucchi, Marco ^a   Mussi, Alfredo ^a   Mutti, Luciano ^d  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Pulmonary Unit   (Italy)

^d Empoli Local Health Unit 11   (Italy)

Author keywords

Marker; Mesothelioma; Osteopontin

Indexed keywords

ASBESTOS; OSTEOPONTIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CIGARETTE SMOKING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PLASMA; PLEURA MESOTHELIOMA; PROTEIN BLOOD LEVEL; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SERUM; SPIROMETRY; STORAGE; TEMPERATURE; THAWING; THORAX RADIOGRAPHY;

EID: 78650820295     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500307     Document Type: Article

References (25)

1. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005; 65: 3049-52. (Pubitemid 40524583)
2. Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res 2008; 659: 126-36.
3. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-72.
4. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008; 112: 144-50.
5. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90. (Pubitemid 38114178)
6. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14: 373-81.
7. Fujihara S, Yokozeki M, Oba Y, Higashibata Y, Nomura S, Moriyama K. Function and regulation of osteopontin in response to mechanical stress. J. Bone Miner Res 2006; 21: 956-64. (Pubitemid 43788002)
8. O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-56.
9. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-41.
10. Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130: 58-64.
11. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-73.
12. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-35.
13. Park E, Thomas PS, Johnson AR, Yates DH. Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 2009; 15: 1362-6.
14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. ATS/ERS Task Force. Eur Respir J 2005; 26: 319-38.
15. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-35.
16. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006; 163: 670-5.
17. SPSS/PC Statistical Package for the Social Sciences + update for 10.1, 2000. SPSS Inc, Chicago, IL, USA.
18. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004; 5: 290-8.
19. Immuno-Biological Laboratories (IBL) Co., Ltd. Instructions for Human Osteopontin Assay Kit. Available from http://www.ibl-japan.co.jp.
20. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851-7.
21. Paleari L, Rotolo N, Imperatori A, et al. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 2009; 24: 112-7.
22. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-81.
23. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007; 132: 1239-46. (Pubitemid 47620999)
24. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6.
25. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008; 62: 45-54.